Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,763.96
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
104.30
(
-0.12%
)
Bitcoin
70,510.01
(
0.87%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ghmm post# 145677

Wednesday, 07/18/2012 10:59:14 AM

Wednesday, July 18, 2012 10:59:14 AM

Post# of 257262

Do you think payers will favor reimbursing gammagard vs. others in that scenario? I was also wondering if the results are positive but treatment effect is marginal if insurers will try to make patients use other treatments (like aricept and namenda).

Good questions. My guesses are: 1) no; 2) yes.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now